Showing results (61-70 of 88) with videos related to
Sort By:
Pageof 9
The New England Journal of Medicine|June 4, 2013
Nivolumab plus ipilimumab in advanced melanomaJedd D Wolchok, Harriet Kluger, Margaret K Callahan, et al.Blood Cancer Journal|July 2, 2025
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignanciesSigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, et al.Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid TumorsTae Won Kim, Howard A Burris, Maria J de Miguel Luken, et al.Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.Blood Cancer Discovery|October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic CentersMalin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.Pageof 9